Phaseline

Companies › OnKure

OnKure: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OKI-219–Phase 1Advanced CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06239467OKI-219Phase 1Advanced CancerOncologyDec 2026

From the company's SEC filings

Cash and short-term investments of $163m on 2026-09-30; operating cash outflow about $49m a year; runway about 40 months at that burn, to Feb 2030

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.